메뉴 건너뛰기
Liver International
Volumn 29, Issue 7, 2009, Pages 1126-1127
Which level of immunosuppression is harmful for occult hepatitis B virus infection?
Author keywords

[No Author keywords available]
Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; HEPATITIS B SURFACE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; STEROID; VIRUS DNA;
EID: 67650504238     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02050.x     Document Type: Letter
Times cited : (2)
References (7)
  • 1
    • 59849117376 scopus 로고    scopus 로고
    • Occult hepatitis B virus infection in patients with autoimmune liver diseases
    • Georgiadou SP, Zachou K, Liaskos C, et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009; 29: 434-42.
    • (2009) Liver Int , vol.29 , pp. 434-442
    • Georgiadou, S.P.1    Zachou, K.2    Liaskos, C.3
  • 2
    • 42649097566 scopus 로고    scopus 로고
    • The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting
    • Barclay S, Pol S, Mutimer D, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008; 42: 104-15.
    • (2008) J Clin Virol , vol.42 , pp. 104-115
    • Barclay, S.1    Pol, S.2    Mutimer, D.3
  • 3
    • 34047151232 scopus 로고    scopus 로고
    • Prophylaxis and treatment of hepatitis B in immunocompromised patients
    • Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
    • (2007) Dig Liver Dis , vol.39 , pp. 397-408
    • Marzano, A.1    Angelucci, E.2    Andreone, P.3
  • 4
    • 33846972329 scopus 로고    scopus 로고
    • Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies
    • Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
    • (2007) Br J Haematol , vol.136 , pp. 699-712
    • Lalazar, G.1    Rund, D.2    Shouval, D.3
  • 5
    • 2342560548 scopus 로고    scopus 로고
    • Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
    • Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
    • (2004) Br J Cancer , vol.90 , pp. 1306-1311
    • Yeo, W.1    Zee, B.2    Zhong, S.3
  • 6
    • 84984575715 scopus 로고    scopus 로고
    • Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
    • Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-8.
    • (2003) Hepatology , vol.37 , pp. 1320-1328
    • Cheng, A.L.1    Hsiung, C.A.2    Su, I.J.3
  • 7
    • 50949118651 scopus 로고    scopus 로고
    • Statements from the Taormina expert meeting on occult hepatitis B virus infection
    • Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
    • (2008) J Hepatol , vol.49 , pp. 652-657
    • Raimondo, G.1    Allain, J.P.2    Brunetto, M.R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.